MedTrace Logo

Long Term Outcome of Intravitreal Ranibizumab for ROP

NCT04537065 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2020-09-03

No results posted yet for this study

Summary

premature infants who had a history of intravitreal injection of (Ranibizumab) not less than one year were examined for refractive state and biometry

Conditions

  • Retinopathy of Prematurity

Interventions

OTHER

cycloplegic refraction

Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder. The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).

Sponsors & Collaborators

  • Ameera Gamal Abdelhameed

    lead OTHER

Principal Investigators

  • Rania MR Bassiouny, MD · Mansoura University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2018-09-01
Completion
2018-09-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04537065 on ClinicalTrials.gov